Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
Powered by cricketnext logo
News18 » Business
1-min read

Aurobindo Pharma Shares Plunge 19% on US FDA Observations on Telangana Plant

At 3:10pm, shares of Aurobindo Pharma were trading at Rs 460.85, down 18.8%, after hitting an intra-day low of Rs 459.20. The stock has lost 23% in the last one year.

Trending Desk

Updated:October 7, 2019, 5:21 PM IST
facebookTwitter Pocket whatsapp
Aurobindo Pharma Shares Plunge 19% on US FDA Observations on Telangana Plant
Image for representation.

New Delhi: Aurobindo Pharma Ltd shares plunged as much as 19% in intra-day trade on Monday, i.e. 7 October, after the US health regulator issued adverse observations on the company’s manufacturing facility in Telangana.

At 3:10pm, shares of Aurobindo Pharma were trading at Rs 460.85, down 18.8%, after hitting an intra-day low of Rs 459.20. The stock has lost 23% in the last one year.

According to reports, the US Food and drug Administration (FDA) had conducted an inspection at Aurobindo’s Unit-7 between 19 September and 27 September 2019, after which a note was issued by the regulator indicating procedural lapses along with lack of quality control.

The Form 483 (inspection report) issued by the US FDA made the following seven observations about Aurobindo Pharma’s Unit-7: 1) Failure to review any unexplained discrepancy; 2) failure to consider failure of batch or components; 3) Control procedures not established; 4) No written procedures for production and process controls; 5) Equipment and utensils not cleaned at appropriate levels; 6) Procedures applicable to quality control not thoroughly followed; and 7) Written production and process controls not developed in execution of production, process controls.

Amey Chalke, pharma analyst at HDFC Securities, told BloombergQuint that Unit-7 was important for Aurobindo Pharma as there were more than 130 product approvals in place from the facility, with over 30 still pending with the US FDA. The revenue contribution could be close to 25-30% to the total US sales. Some of the observations may take some time to resolve, delaying the product approvals from the unit, added Chalke.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Read full article
Next Story
Next Story

facebookTwitter Pocket whatsapp
Most Active
Company Price Change %Gain
Reliance 1,485.50 -1.24
IRCTC 1,927.75 5.30
Indiabulls Hsg 338.30 10.81
Tata Chemicals 764.50 -0.08
HDFC Life 573.75 -0.93
Top Gainers
Company Price Change %Gain
IndusInd Bank 1,181.75 3.57
Tata Steel 443.70 2.48
SBI 327.65 2.31
ONGC 102.85 1.13
Power Grid Corp 189.35 1.01
Top Losers
Company Price Change %Gain
Asian Paints 1,842.85 -2.30
HUL 2,247.85 -1.99
TCS 2,156.30 -1.75
Nestle 16,544.10 -1.38
Tech Mahindra 829.55 -1.36

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results